Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences, Inc. today and set a price target of $57.00.Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Sarepta Therapeutics, and Relmada Therapeutics. According to TipRanks, Ear has an average return of 2.4% and a 41.44% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MBX Biosciences, Inc. with a $75.43 average price target.
Based on MBX Biosciences, Inc.’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $23.52 million. In comparison, last year the company had a GAAP net loss of $23.88 million
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is neutral on the stock. Last month, Salomon Azoulay, the CMO of MBX sold 231.00 shares for a total of $6,823.74.
